Summary by Moomoo AI
On February 14, 2024, ZyVersa Therapeutics, Inc., a biopharmaceutical company based in Delaware, filed a Form S-8 registration statement with the Securities and Exchange Commission (SEC). This filing pertains to the registration of additional shares for the company's 2022 Omnibus Equity Incentive Plan. The registration includes 276,368 additional shares of common stock, which are to be issued under the plan. This total comprises 114,286 shares approved by stockholders during the annual meeting on October 31, 2023, and 162,082 shares authorized under the Plan's Evergreen Provision, which automatically increases the number of shares available each year. The Plan's Evergreen Provision took effect on January 1, 2024, with the mentioned increase. The filing also references a 1-for-35 reverse stock split of the company's common stock, which took effect on December 4, 2023. As of February 13, 2024, ZyVersa Therapeutics had 4,631,987 shares of common stock outstanding. The Form S-8 incorporates by reference various financial documents, including the company's latest audited financial statements and quarterly reports, and details the indemnification provisions for directors and officers.